Treatment of cutaneous tumors with topical 5% imiquimod cream

Clinics

Volumn 64, Issue 10, 2009, Pages 961-966

  Alessi, Sabrina Sisto ^a   Sanches, Jose Antonio ^a   de Oliveira, Walmar Roncalli ^a   Messina, Maria Cristina ^a   Pimentel, Raul de Almeida ^a   Neto, Cyro Festa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Basal cell carcinoma; Imiquimod; Immunomodulator; Immunotherapy; Non melanoma skin cancer

Indexed keywords

EID: 70350534708     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322009001000005     Document Type: Article

References (16)

1. Gaspari AA, Sauder DN. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg. 2003;29:1027-34.
2. Sullivan TP, DeAraujo T, Vincek V, Berman B. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003;29:1181-6.
3. Sterry S, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227-36.
4. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinomas: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dematol. 2004;50: 722-33.
5. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment os superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939-47.
6. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod for the tyreatment of nodular basal cell carcinoma: comparison of dosing regimes. Arch Dermatol. 2002;138:1165-71.
7. Schiessl C, Wolber C, Tauber M, Offner F, Strohal R. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007;6:507-13.
8. Warshauer E, Warshauer BL. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol 2008;7: 447-51.
9. Cowen E, Mercurio MG, Gaspari AA. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol. 2002;47:240-8.
10. Drehs MM, Cook-Bolden F, Tanzi EL, Weinberg JM. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg. 2002;28:427-9.
11. Micali G, De Pasquale R, Caltabiano R, Impallomeni R, Lacarrubba F. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatol Treatment. 2002;13:123-7.
12. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Tebbs V, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15:374-81.
13. Festa Neto C. Tratamento tópico do carcinoma basocelular superficial e nodular pelo imiquimode creme a 5%: observação de 10 casos. An Bras Dermatol. 2002;77:693-8.
14. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;1:1002-7.
15. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose multiple response trial.J Am Acad Dermatol. 2001; 44:807-13.
16. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50: 722-33.